Home » ADAMS RESPIRATORY SWINGS TO 3Q PROFIT
ADAMS RESPIRATORY SWINGS TO 3Q PROFIT
Pharmaceutical company Adams Respiratory Therapeutics Inc. said Thursday that it swung to a third-quarter profit due to the lack of a preferred dividend payment and strong sales of over-the-counter respiratory drug Mucinex.
Business Week
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May